Cargando…

A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration

PARP inhibitors, such as rucaparib, have been well characterized in metastatic castration-resistant prostate cancer (mCRPC) associated with BRCA alterations, and the clinical activity of these agents has also been evaluated in patients with mCRPC associated with alterations in other non-BRCA DNA dam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sautois, Brieuc, Loehr, Andrea, Watkins, Simon P., Schroeder, Hélène, Abida, Wassim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221801/ https://www.ncbi.nlm.nih.gov/pubmed/35735442 http://dx.doi.org/10.3390/curroncol29060333

Ejemplares similares

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
por: Abida, Wassim, et al.
Publicado: (2020)

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
por: Labadie, Brian W, et al.
Publicado: (2022)

Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?
por: Elias, Roy, et al.
Publicado: (2023)

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
por: Fizazi, Karim, et al.
Publicado: (2022)

What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib
por: Petrylak, Daniel P., et al.
Publicado: (2022)

Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
por: Xu, Wen, et al.
Publicado: (2023)

Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor
por: Greenhough, Luke A., et al.
Publicado: (2023)

Homologous Pairing Activities of Two Rice RAD51 Proteins, RAD51A1 and RAD51A2
por: Morozumi, Yuichi, et al.
Publicado: (2013)

Roles of XRCC2, RAD51B and RAD51D in RAD51-Independent SSA Recombination
por: Serra, Heïdi, et al.
Publicado: (2013)

Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells
por: Cho, Hye-yon, et al.
Publicado: (2021)

A Polar and Nucleotide-Dependent Mechanism of Action for RAD51 Paralogs in RAD51 Filament Remodeling
por: Taylor, Martin R.G., et al.
Publicado: (2016)

Polymorphisms of Homologous Recombination RAD51, RAD51B, XRCC2, and XRCC3 Genes and the Risk of Prostate Cancer
por: Nowacka-Zawisza, Maria, et al.
Publicado: (2015)

Arabidopsis RAD51, RAD51C and XRCC3 proteins form a complex and facilitate RAD51 localization on chromosomes for meiotic recombination
por: Su, Hang, et al.
Publicado: (2017)

Rad51 Paralogs Remodel Pre-synaptic Rad51 Filaments to Stimulate Homologous Recombination
por: Taylor, Martin R.G., et al.
Publicado: (2015)

Nucleotide proofreading functions by nematode RAD51 paralogs facilitate optimal RAD51 filament function
por: Špírek, Mário, et al.
Publicado: (2021)

Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations
por: Wu, Maximillian S, et al.
Publicado: (2022)

Rad51 paralogs Rad55-Rad57 balance the anti-recombinase Srs2 in Rad51 filament formation
por: Liu, Jie, et al.
Publicado: (2011)

TODRA, a lncRNA at the RAD51 Locus, Is Oppositely Regulated to RAD51, and Enhances RAD51-Dependent DSB (Double Strand Break) Repair
por: Gazy, Inbal, et al.
Publicado: (2015)

RAD51AP2, a novel vertebrate- and meiotic-specific protein, shares a conserved RAD51-interacting C-terminal domain with RAD51AP1/PIR51
por: Kovalenko, Oleg V., et al.
Publicado: (2006)

Contributions of the RAD51 N-terminal domain to BRCA2-RAD51 interaction
por: Subramanyam, Shyamal, et al.
Publicado: (2013)

RAD51AP1 mediates RAD51 activity through nucleosome interaction
por: Pires, Elena, et al.
Publicado: (2021)

Hot on RAD51C: structure and functions of RAD51C‐XRCC3
por: Szakal, Barnabas, et al.
Publicado: (2023)

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
por: Shapiro, Geoffrey I., et al.
Publicado: (2018)

The Shu complex interacts with Rad51 through the Rad51 paralogues Rad55–Rad57 to mediate error-free recombination
por: Godin, Stephen, et al.
Publicado: (2013)

Rad51 and Rad54 ATPase activities are both required to modulate Rad51-dsDNA filament dynamics
por: Li, Xuan, et al.
Publicado: (2007)

Rad51, friend or foe?
por: Tan-Wong, Sue Mei, et al.
Publicado: (2013)

RAD51 wrestles with SUMO
por: Kee, Younghoon, et al.
Publicado: (2022)

RAD51: Beyond the break
por: Wassing, Isabel E., et al.
Publicado: (2021)

Noncanonical Roles of RAD51
por: Thomas, Mélissa, et al.
Publicado: (2023)

RAD-ical New Insights into RAD51 Regulation
por: Sullivan, Meghan R., et al.
Publicado: (2018)

Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer
por: Denis, Chloé, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

IKKε Inhibitor Amlexanox Promotes Olaparib Sensitivity through the C/EBP-β-Mediated Transcription of Rad51 in Castrate-Resistant Prostate Cancer
por: Gilbert, Sophie, et al.
Publicado: (2022)

Functional significance of the Rad51-Srs2 complex in Rad51 presynaptic filament disruption
por: Colavito, Sierra, et al.
Publicado: (2009)

RAD51 paralogs synergize with RAD51 to protect reversed forks from cellular nucleases
por: Guh, Chia-Lun, et al.
Publicado: (2023)

Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
por: Yehya, Amani, et al.
Publicado: (2022)

Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D
por: Yang, Xin, et al.
Publicado: (2020)

Rad52-Rad51 association is essential to protect Rad51 filaments against Srs2, but facultative for filament formation
por: Ma, Emilie, et al.
Publicado: (2018)

RAD51 and XRCC3 Polymorphisms Are Associated with Increased Risk of Prostate Cancer
por: Nowacka-Zawisza, Maria, et al.
Publicado: (2019)

Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
por: Arnold, Peter, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6lq0pf4gpesdr6285bdid80v0b